{"pub": "marketwatch", "url": "https://marketwatch.com/story/aimmunes-stock-halted-as-fda-panels-decision-awaited-on-peanut-allergy-treatment-2019-09-13", "downloaded_at": "2019-09-13 18:09:52.246084+00:00", "title": "Aimmune's stock halted as FDA panel's decision awaited on peanut allergy treatment", "language": "en", "text": "Aimmune Therapeutics Inc.'s stock aimm has been halted for news Friday, as the Food and Drug Administration's Allergenic Products Advisory Committee (APAC) is meeting about the efficacy and safety data of the biopharmaceutical company's treatment for peanut allergies, Palforzia. APAC is discussing whether the data supports licensure of Palforzia as a treatment to reduce the incidence and severity of allergic reactions, including anaphylaxis, after accidental exposure to peanuts in patients 4 through 17 years of age. The meeting had been scheduled from 8:30 a.m. Eastern to 4:30 p.m. Aimmune's stock had gained 25% this week through Thursday, and has advanced 3.1% year to date, while the iShares Nasdaq Biotechnology ETF IBB, +0.38% has climbed 8.6% this year and the S&P 500 SPX, +0.00% has run up 20.3%.", "description": "Aimmune Therapeutics Inc.'s stock has been halted for news Friday, as the Food and Drug Administration's Allergenic Products Advisory Committee (APAC) is...", "authors": ["Tomi Kilgore", "Reporter"], "top_image": "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png", "published_at": "2019-09-13"}